Disease and Therapy Review: Generalized Anxiety Disorder

Disease and Therapy Review: Generalized Anxiety Disorder
  • Report price : $ 750
  • Publication date : September 2009

Get this Report Now !

Disease and Therapy Review: Generalized Anxiety Disorder


The Generalized Anxiety Disorder (GAD) Disease and Therapy Review provides an overview of the disease and related conditions, with incidence and prevalence numbers and percentages for major countries worldwide, information on diagnosis, and an overview of treatment. Dosing and treatment cost information is provided for approved treatments. General information on the GAD market is provided. 
 



Disease and Therapy Reviews were developed to provide a basic understanding of the key facts about a disease and market in a quick, easy-to-read format.  These reports are prepared by the senior market research team of Timely Data Resources.  Each Disease and Therapy Review provides a concise analysis of the most important information about a particular disease, its treatment, and the market opportunities.  Reports begin with an overview of the condition, and also contain tables that summarize the available worldwide incidence and prevalence data for the condition, a review of current diagnosis strategies and treatment options, general information about the market size, and information about important market trends.  The data contained in these reports comes from key industry secondary data sources, such as the Timely Data Resources Incidence and Prevalence Database, and Lange's Current Medical Diagnosis and Treatment.  This information is supplemented by reviews of analyst reports, company reports, and medical websites.  Sources and references are provided.  

 

RELATED REPORTS

Oncology Market Leaders - Analyses and Outlook, Market Report  2008-2023

Oncology Market Leaders - Analyses and Outlook, Market Report 2008-2023

  • $ 2 501
  • August 2008

The UK government have told kidney cancer patients that new drugs cannot be offered on the National Health Service. Roche's Avastin, Bayer's Nexavar, Pfizer's Sutent and Wyeth's Torisel were not cost-effective. The drugs -- known generically as bevacizumab, sorafenib, sunitinib and temsirolimus -- s ...

Industries : Pathology

Disease and Therapy Review: Fibromyalgia

Disease and Therapy Review: Fibromyalgia

  • $ 750
  • September 2009

The Fibromyalgia Disease and Therapy Review provides an overview of the disease and related conditions, with prevalence numbers and percentages for major countries worldwide, information on diagnosis, and an overview of treatment. Dosing and treatment cost information is provided for various treatm ...

Industries : Pathology, Therapy

Disease and Therapy Review:  Epilepsy

Disease and Therapy Review: Epilepsy

  • $ 750
  • September 2009

The Epilepsy Disease and Therapy Review provides an overview of the disease and related conditions, with incidence and prevalence numbers and percentages for major countries worldwide, information on diagnosis, and an overview of treatment. Dosing and treatment cost information is provided for vari ...

Industries : Pathology, Therapy

Disease and Therapy Review:  Heart Failure

Disease and Therapy Review: Heart Failure

  • $ 750
  • September 2009

The Heart Failure Disease and Therapy Review provides an overview of the disease and related conditions, with incidence, prevalence, and mortality numbers and percentages for major countries worldwide, information on diagnosis, and an overview of treatment. Dosing and treatment cost information is ...

Industries : Pathology, Therapy

Disease and Therapy Review:  Diabetes

Disease and Therapy Review: Diabetes

  • $ 750
  • September 2009

The Parkinson's Disease Disease and Therapy Review provides an overview of the disease and related conditions, with incidence and prevalence numbers and percentages for major countries worldwide, information on diagnosis, and an overview of treatment. Dosing and treatment cost information is provid ...

Industries : Pathology, Therapy

Disease and Therapy Review:  Hepatitis C

Disease and Therapy Review: Hepatitis C

  • $ 750
  • September 2009

The Hepatitis C Disease and Therapy Review provides an overview of the disease and related conditions, with incidence and prevalence numbers and percentages for major countries worldwide, information on diagnosis, and an overview of treatment. Dosing and treatment cost information is provided for v ...

Industries : Pathology, Therapy

24/7 Customer Service

Contact Clare now !

reportlinker.com © Copyright 2009. All rights reserved

ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.